Stock listing
Frankfurt:PH4 CStone Pharmaceuticals Aktie
German listing (Frankfurt) of CStone Pharmaceuticals · home listing HKEX:2616
Follow CStone Pharmaceuticals into a list and get an email when it puts out news.
Share price · FWB:PH4
€0.638 EUR -0.025 (-3.8%)
Close on Nov 20, 2026
- Day range
- €0.638 – €0.639 EURNov 20, 2026
- Market cap
- €1.02B EURAt the close on Nov 20, 2026 · price × 1.59B shares outstanding
- 52-week range
- €0.445 – €1.111 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €325 EURMedian day 0 shares · 47 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| HKEX:2616 · Home | $5.68 HKD | -0.215 (-3.6%) | 13,966,500 | $6.00 | $6.00 | $5.595 | $5.895 | Close on Nov 20, 2026 |
| OTC:CSPHF | $0.75 USD | +0.061 (+8.8%) | 201 | $0.75 | $0.75 | $0.75 | $0.689 | Close on Nov 17, 2026 |
| Frankfurt:PH4 | €0.638 EUR | -0.025 (-3.8%) | — | €0.639 | €0.639 | €0.638 | €0.663 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:PH4 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.587 | -0.026 | -4.2% | €0.588 | €0.588 | €0.587 | 0 | |
| €0.613 | +0.020 | +3.4% | €0.614 | €0.614 | €0.613 | 0 | |
| €0.593 | +0.065 | +12.3% | €0.596 | €0.597 | €0.593 | 0 | |
| €0.528 | -0.015 | -2.8% | €0.528 | €0.528 | €0.527 | 0 | |
| €0.543 | +0.003 | +0.6% | €0.544 | €0.545 | €0.543 | 0 | |
| €0.540 | +0.020 | +3.8% | €0.540 | €0.540 | €0.535 | 0 | |
| €0.520 | -0.002 | -0.4% | €0.520 | €0.525 | €0.518 | 0 | |
| €0.522 | +0.019 | +3.8% | €0.521 | €0.524 | €0.520 | 0 | |
| €0.503 | -0.034 | -6.3% | €0.504 | €0.506 | €0.498 | 0 | |
| €0.537 | -0.001 | -0.2% | €0.537 | €0.537 | €0.537 | 0 | |
| €0.538 | +0.020 | +3.9% | €0.539 | €0.540 | €0.536 | 0 | |
| €0.518 | -0.038 | -6.8% | €0.521 | €0.523 | €0.516 | 0 | |
| €0.556 | -0.003 | -0.5% | €0.557 | €0.557 | €0.556 | 0 | |
| €0.559 | +0.024 | +4.5% | €0.561 | €0.561 | €0.551 | 0 | |
| €0.535 | -0.007 | -1.3% | €0.534 | €0.538 | €0.530 | 0 | |
| €0.542 | +0.017 | +3.2% | €0.576 | €0.577 | €0.537 | 0 | |
| €0.525 | -0.008 | -1.5% | €0.526 | €0.526 | €0.525 | 0 | |
| €0.533 | -0.018 | -3.3% | €0.533 | €0.533 | €0.533 | 0 | |
| €0.551 | -0.002 | -0.4% | €0.552 | €0.553 | €0.551 | 0 | |
| €0.553 | -0.007 | -1.3% | €0.587 | €0.594 | €0.547 | 10 | |
| €0.560 | -0.018 | -3.1% | €0.566 | €0.567 | €0.554 | 0 | |
| €0.578 | -0.052 | -8.3% | €0.581 | €0.584 | €0.577 | 10 | |
| €0.630 | -0.016 | -2.5% | €0.637 | €0.637 | €0.630 | 0 | |
| €0.646 | +0.016 | +2.5% | €0.652 | €0.656 | €0.646 | 0 | |
| €0.630 | +0.004 | +0.6% | €0.635 | €0.662 | €0.630 | 128 | |
| €0.626 | -0.018 | -2.8% | €0.627 | €0.628 | €0.618 | 0 | |
| €0.644 | +0.004 | +0.6% | €0.645 | €0.653 | €0.642 | 0 | |
| €0.640 | +0.032 | +5.3% | €0.634 | €0.646 | €0.627 | 20,000 | |
| €0.608 | +0.047 | +8.4% | €0.608 | €0.608 | €0.607 | 0 | |
| €0.561 | -0.018 | -3.1% | €0.565 | €0.565 | €0.555 | 0 | |
| €0.579 | -0.010 | -1.7% | €0.582 | €0.584 | €0.578 | 0 | |
| €0.589 | -0.038 | -6.1% | €0.596 | €0.596 | €0.586 | 0 | |
| €0.627 | +0.007 | +1.1% | €0.629 | €0.634 | €0.624 | 0 | |
| €0.620 | +0.008 | +1.3% | €0.619 | €0.621 | €0.619 | 0 | |
| €0.612 | +0.038 | +6.6% | €0.615 | €0.619 | €0.607 | 0 | |
| €0.574 | -0.016 | -2.7% | €0.574 | €0.574 | €0.572 | 2 | |
| €0.590 | +0.038 | +6.9% | €0.602 | €0.608 | €0.588 | 82 | |
| €0.552 | -0.093 | -14.4% | €0.557 | €0.558 | €0.550 | 0 | |
| €0.645 | -0.012 | -1.8% | €0.643 | €0.645 | €0.642 | 0 | |
| €0.657 | +0.045 | +7.4% | €0.654 | €0.659 | €0.651 | 0 | |
| €0.612 | -0.043 | -6.6% | €0.612 | €0.612 | €0.612 | 0 | |
| €0.655 | +0.005 | +0.8% | €0.656 | €0.657 | €0.655 | 0 | |
| €0.650 | -0.017 | -2.5% | €0.653 | €0.654 | €0.647 | 0 | |
| €0.667 | +0.019 | +2.9% | €0.668 | €0.668 | €0.660 | 0 | |
| €0.648 | -0.090 | -12.2% | €0.649 | €0.657 | €0.645 | 0 | |
| €0.738 | +0.071 | +10.6% | €0.678 | €0.738 | €0.678 | 38 | |
| €0.667 | -0.051 | -7.1% | €0.670 | €0.689 | €0.663 | 4,000 | |
| €0.718 | +0.101 | +16.4% | €0.670 | €0.719 | €0.657 | 4,000 | |
| €0.617 | +0.001 | +0.2% | €0.621 | €0.627 | €0.617 | 0 | |
| €0.616 | -0.058 | -8.6% | €0.621 | €0.622 | €0.613 | 0 | |
| €0.674 | +0.001 | +0.1% | €0.635 | €0.675 | €0.634 | 38 | |
| €0.673 | +0.041 | +6.5% | €0.680 | €0.680 | €0.672 | 0 | |
| €0.632 | +0.009 | +1.4% | €0.632 | €0.632 | €0.632 | 0 | |
| €0.623 | +0.036 | +6.1% | €0.624 | €0.624 | €0.621 | 0 | |
| €0.587 | +0.012 | +2.1% | €0.590 | €0.590 | €0.583 | 0 | |
| €0.575 | +0.019 | +3.4% | €0.581 | €0.581 | €0.569 | 0 | |
| €0.556 | -0.004 | -0.7% | €0.576 | €0.578 | €0.556 | 0 |
- Ticker
- Frankfurt:PH4
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 20, 2026
Grant of share options and restricted share units
Latest deck · Aug 28, 2026
H1 2026 Earnings Presentation
Earnings · 61 slides
Latest news
Monthly return of equity issuer on movements in securities for the month ended 31 October 2026
Nov 5, 2026
Closed €0.613 (+3.4%) on Nov 5, 2026
Voluntary announcement - cstone and kimia therapeutics enter clinical development collaboration to advance a novel drug candidate targeting repair pathways critical for solid tumor survival
Nov 4, 2026
Closed €0.593 (+12.3%) on Nov 4, 2026
Voluntary announcement - cstone announces major clinical validation milestone for CS2009 at ESMO 2026: data from more than 300 patients support mechanism, safety and broad antitumor activity
Oct 25, 2026
Closed €0.537 (-0.2%) on Oct 26, 2026
Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
Oct 7, 2026
Closed €0.63 (-2.5%) on Oct 7, 2026
Interim report 2026
Sep 28, 2026
Closed €0.561 (-3.1%) on Sep 28, 2026
Voluntary announcement - increase in shareholding by CEO and executive director dr. jianxin yang by 496,000 shares, with accumulated purchase totaling 14,210,500 shares
Sep 24, 2026
Closed €0.589 (-6.1%) on Sep 24, 2026
CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
Aug 27, 2026
Closed €0.674 (+0.1%) on Aug 28, 2026
CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand
Jun 25, 2026
Closed €0.494 (-5.0%) on Jun 25, 2026
CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
Jun 11, 2026
Closed €0.477 (+3.9%) on Jun 11, 2026
CStone Pharmaceuticals on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 33 in all · newest Nov 20, 2026 · oldest 2024
- Decks
- 23 decks · latest Aug 28, 2026
Where CStone Pharmaceuticals is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| HKEX:2616 基石藥業 · Home listing | HKEX | Hong Kong | HKD |
| gettex:PH4 | gettex | Germany | EUR |
| LS Exchange:A2PEFW | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2PEFW | Lang & Schwarz | Germany | EUR |
| OTC:CSPHF | OTC | United States | USD |
| Stuttgart:PH4 | Stuttgart | Germany | EUR |
| Dusseldorf:PH4 | Dusseldorf | Germany | EUR |
| Frankfurt:PH4 · This page | Frankfurt | Germany | EUR |
| Munich:PH4 | Munich | Germany | EUR |
| Tradegate:PH4 | Tradegate | Germany | EUR |
Valuation
EV/sales 24.1× against a median of 36.1×: 3rd lowest of 6 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $7.64B HKD
- P/E
- Loss
- EV/sales
- 24.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 6.0×
- Gross margin
- 19.0%
- Operating margin
- −160.5%
- Net margin
- −162.1%
- Debt to equity
- 0.3×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| CStone Pharmaceuticals · HKEX:2616 | US$1.16B | US$974.6M | n/a | 24.1× | n/a | 6.0× | −162.1% | 0.3× | n/a |
| Taysha Gene Therapies, Inc. · NASDAQ:TSHA | US$1.21B | US$837.4M | n/a | 153× | n/a | 3.4× | n/a | 0.1× | 1.69 |
| Mineralys Therapeutics, Inc. · NASDAQ:MLYS | US$1.21B | US$585.1M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 1.39 |
| GH Research PLC · NASDAQ:GHRS | US$1.20B | US$841.0M | n/a | n/a | n/a | 3.4× | n/a | 0.0× | 1.28 |
| Vor Biopharma Inc. · NASDAQ:VOR | US$1.18B | US$697.4M | 0.9× | n/a | n/a | n/a | n/a | n/a | 1.25 |
| Staidson (Beijing) Biopharmaceuticals Co. Ltd. Class A · SZSE:300204 | US$1.17B | US$1.01B | n/a | 36.1× | n/a | 3.9× | −53.3% | 0.0× | n/a |
| OPKO Health, Inc. · NASDAQ:OPK | US$1.17B | US$1.26B | n/a | 2.5× | n/a | 1.0× | −29.5% | 0.4× | 0.90 |
| D&D Pharmatech Co., Ltd. · KRX:347850 | US$1.15B | US$1.12B | n/a | 549× | n/a | 11.5× | −785.5% | 0.8× | n/a |
| Structure Therapeutics, Inc. · NASDAQ:GPCR | US$1.15B | −US$82.92M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 1.38 |
| COMPASS Pathways Plc · NASDAQ:CMPS | US$1.14B | US$747.8M | n/a | n/a | n/a | 8.0× | n/a | 0.4× | 1.65 |
| Ascentage Pharma Group International · HKEX:6855 | US$1.11B | US$1.14B | n/a | 13.6× | n/a | 13.3× | −216.5% | 3.8× | n/a |
| Median of the others | US$1.17B | US$839.2M | 0.9× | 36.1× | 3.4× | −134.9% | 0.1× | 1.38 |
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 15.60 HKD · Analysts' mean
- EPS, year to Dec 2026
- -0.29 · 1 analyst
- Revenue, year to Dec 2026
- 423.2M · 2 analysts
Team and board
| Officer | Role |
|---|---|
| Jason Yang | Chief Executive Officer, President of R&D |
| Weicong Ni | Chief Financial Officer and Company Secretary |
| Yinghua Zhang | Chief Operating Officer |
| Michael Choi | Chief Business and Strategy Officer |
| Qingmei Shi | Chief Medical Officer |
| Qinzhou Qi | Head of R&D Management and Chief of Staff to the CEO |
| Yujuan La | Head of Product Development |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Aug 14, 2025 · Before open | +0.4% |
| Quarter to Mar 31, 2025 | Apr 28, 2025 | +0.3% |
| Q4 2024 | Mar 27, 2025 | −1.5% |
| Q4 2022 | Mar 15, 2023 · Before open | +7.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| H1 2026 Earnings Presentation | Earnings | 61 slides | Aug 28, 2026 |
| FY2025 Earnings Presentation | Earnings | 43 slides | Mar 27, 2026 |
| H1 2025 Earnings Presentation | Earnings | 41 slides | Aug 15, 2025 |
| FY2024 Earnings Presentation | Earnings | 65 slides | Mar 28, 2025 |
| Investor Presentation (November 2024) | Investor deck | 44 slides | November 2024 |
| H1 2024 Earnings Presentation | Earnings | 40 slides | Aug 26, 2024 |
| FY2023 Earnings Presentation | Earnings | 38 slides | Mar 28, 2024 |
| FY2023 Earnings Presentation | Earnings | 38 slides | Mar 28, 2024 |
| Corporate Update (December 2023) | Corporate update | 34 slides | Dec 20, 2023 |
| H1 2023 Earnings Presentation | Earnings | 26 slides | Aug 16, 2023 |
All 23 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| FY2022 Earnings Presentation | Earnings | 33 slides | Mar 16, 2023 |
| FY2021 Earnings Presentation | Earnings | 34 slides | Jun 1, 2022 |
| Investor Presentation (May 2022) | Investor deck | 35 slides | May 2022 |
| Investor Presentation (April 2022) | Investor deck | 35 slides | April 2022 |
| Investor Presentation (February 2022) | Investor deck | 35 slides | February 2022 |
| Investor Presentation (January 2022) | Investor deck | 35 slides | January 2022 |
| Investor Presentation (November 2021) | Investor deck | 34 slides | November 2021 |
| H1 2021 Earnings Presentation | Earnings | 31 slides | Aug 27, 2021 |
| Investor Presentation (June 2021) | Investor deck | 33 slides | June 2021 |
| Investor Presentation (June 2021) | Investor deck | 34 slides | June 2021 |
| Investor Presentation (March 2021) | Investor deck | 32 slides | March 2021 |
| Investor Presentation (September 2020) | Investor deck | 36 slides | September 2020 |
| Investor Presentation (April 2020) | Investor deck | 37 slides | April 2020 |
Financials
Annual, in CNY
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 269.6M | 407.2M | 463.8M | 481.4M | 243.7M | 1.04B | 0 | 12.6M | 10.3M | 0 |
| Cost of revenue | 218.3M | 167.1M | 159.5M | 203.0M | 106.8M | 241.4M | 0 | 0 | 0 | |
| Gross profit | 51.2M | 240.2M | 304.3M | 278.4M | 136.9M | 797.4M | 12.6M | 10.3M | 0 | |
| Research and development | 311.5M | 134.7M | 527.8M | 614.2M | 1.30B | 1.40B | 1.40B | 850.2M | 213.4M | 247.1M |
| Selling, general and administrative | 87.3M | 33.2M | 48.7M | 63.2M | 109.2M | 86.7M | 338.6M | 191.0M | 39.3M | 15.1M |
| Operating income | -432.6M | -91.7M | -605.6M | -912.1M | -1.83B | -1.09B | -1.74B | -1.03B | -242.5M | -262.2M |
| Depreciation and amortization | 44.0M | 49.8M | 58.2M | 44.5M | 22.7M | 14.8M | 11.6M | 5.27M | 823.4K | 69.0K |
| EBITDA | -388.6M | -41.9M | -547.4M | -867.6M | -1.81B | -1.08B | -1.73B | -1.02B | -241.7M | -262.1M |
| Interest expense | 12.9M | 15.2M | 11.8M | 8.48M | 2.24M | 1.32M | 303.0K | 745.6M | 60.0K | 240.0K |
| Income before tax | -423.9M | -91.2M | -367.2M | -902.7M | -1.92B | -1.22B | -2.31B | -1.79B | -342.5M | -253.0M |
| Income tax | 13.1M | 61.9M | 67.3M | -1.10M | 748.4M | -734.0M | 0 | 0 | ||
| Net income | -437.0M | -91.2M | -367.2M | -902.7M | -1.92B | -1.22B | -2.31B | -1.75B | -308.9M | -246.1M |
| Earnings per share, basic | -0.31 | -0.07 | -0.29 | -0.77 | -1.65 | -1.04 | -2.34 | -1.77 | -0.31 | -0.25 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 754.0M | 387.9M | 996.7M | 558.7M | 742.7M | 3.02B | 1.13B | 701.3M | 83.4M | 59.5M |
| Short-term investments | 165.1M | 285.0M | 51.9M | 483.4M | 983.6M | 369.0M | 1.62B | 856.6M | 454.3M | 752.4M |
| Receivables | 33.8M | 130.9M | 172.4M | 77.1M | 117.6M | 0 | 760.0K | |||
| Inventory | 116.9M | 286.1M | 108.8M | 22.2M | 61.4M | 0 | ||||
| Current assets | 1.11B | 1.09B | 1.33B | 1.25B | 1.96B | 3.57B | 2.89B | 1.60B | 545.3M | 824.8M |
| Property, plant and equipment | 130.5M | 153.4M | 206.6M | 182.8M | 102.0M | 18.7M | 14.5M | 15.5M | 1.03M | |
| Total assets | 1.36B | 1.39B | 1.66B | 1.64B | 2.27B | 3.76B | 2.95B | 1.63B | 564.3M | 826.1M |
| Accounts payable | 77.2M | 338.0M | 246.4M | 290.4M | 414.3M | 28.0M | 37.3M | 4.56M | 302.0K | |
| Current liabilities | 510.4M | 682.0M | 850.3M | 946.5M | 932.9M | 727.0M | 458.0M | 1.11B | 113.2M | 59.2M |
| Long-term debt | 156.5M | 257.4M | 213.0M | 219.0M | 115.8M | 54.3M | ||||
| Total debt | 348.7M | 356.0M | 363.4M | 286.3M | 174.2M | 75.2M | 1.62B | |||
| Total liabilities | 741.6M | 1.03B | 1.21B | 1.19B | 1.06B | 808.3M | 469.1M | 1.12B | 113.2M | 59.2M |
| Shareholders' equity | 617.0M | 363.9M | 456.8M | 449.3M | 1.21B | 2.95B | 2.48B | 515.3M | 426.3M | 712.7M |
| Shares outstanding | 1.39B | 1.28B | 1.26B | 1.17B | 1.17B | 1.17B | 984.5M | 984.1M | 984.1M | 984.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -327.7M | -343.2M | -588.8M | -612.5M | -1.48B | -508.1M | -1.08B | -791.1M | -240.2M | -213.0M |
| Capital spending | 0 | 0 | -65.0M | -101.8M | -149.1M | -71.4M | -10.4M | -7.91M | -12.5M | -1.11M |
| Free cash flow | -327.7M | -343.2M | -653.9M | -714.3M | -1.63B | -579.5M | -1.09B | -799.0M | -252.7M | -214.1M |
| Cash from investing | 134.0M | -247.7M | 619.6M | 365.1M | -826.6M | 1.18B | -658.9M | -377.7M | 268.3M | -753.5M |
| Cash from financing | 577.8M | -12.9M | 388.4M | 28.5M | 92.3M | 1.39B | 2.09B | 1.66B | -300.0K | 1.01B |
| Share buybacks | 74.0K | 341.8M | 2.53M | 16.8M | -21.8M | 2.20B | 1.66B | 0 | 706.5M | |
| Change in cash | 365.8M | -608.7M | 438.0M | -184.0M | -2.28B | 1.90B | 425.1M | 617.9M | 23.9M | 59.5M |
Filings
Cap table
Built by 6ix from CStone Pharmaceuticals’ releases
- Common shares
- 1,594,112,329
- Fully diluted
- 1,594,112,329
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,594,112,329 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,594,112,329 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jason Yang | Chief Executive Officer, President of R&D · Since at least Aug 27, 2026 |
| Michael Choi | Chief Business and Strategy Officer · Since at least Nov 5, 2026 |
| Qingmei Shi | Chief Medical Officer · Since at least Feb 23, 2026 |
| Qinzhou Qi | Head of R&D Management and Chief of Staff to the CEO · Since at least Nov 5, 2026 |
| Weicong Ni | Chief Financial Officer and Company Secretary · Since at least Nov 5, 2026 |
| Yinghua Zhang | Chief Operating Officer · Since at least Nov 5, 2026 |
| Yujuan La | Head of Product Development · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about CStone Pharmaceuticals.